Review of icatibant use in the Winnipeg Regional Health Authority

Table 3 Timeline to treatment, Allergist consult, icatibant dispensation and administration

Event	Stratification	n	Median time (IQR), from ED presentation, hours	p-value (*< 0.05)	n	Median time (IQR), from last event, hours	p-value (*< 0.05)
ER presentation	NA	22	0	NA	NA	0	NA
Conventional treatment	NA	12	1.29 (0.25–3.89)		12	See left
Allergist consult	Unstratified	22	1.77 (0.59–5.51)		N/A
	Conventional^a	11	4.15 (0.85–15.63)	0.10	11	2.42 (0.42–4.08)
	Without^b	11	1.15 (0.43–2.03)	0.10	11	See left
Pharmacy dispensation	Unstratified	22	2.40 (0.87–6.15)	NA	22	0.40 (0.22–0.98)
	Conventional^a	11	5.75 (1.69–16.67)	0.03*	11	0.60 (0.23–1.60)	0.10
	Without^b	11	1.35 (0.60–2.88)	0.03*	11	0.35 (0.17–0.80)	0.10
Icatibant administration	Unstratified	21^c	2.95 (1.58–7.05)	NA	21^c	0.55 (0.35–0.80)	NA
	Conventional^a	10	7.78 (2.45–17.47)	0.03*	10	0.77 (0.55–0.82)	0.10
	Without^b	11	2.06 (1.18–3.27)	0.03*	11	0.38 (0.23–0.75)	0.10

NA not applicable, IQR inter-quartile range
^aConventional = treated first with conventional treatment
^bWithout = no initial conventional treatment
^cOne patient was not administered icatibant due to symptom relief and was excluded from this analysis

ISSN: 1710-1492